ASC30
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
Ascletis Pharma (China) Co · Phase 2 · Completed · Enrollment 125
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Cohort 1 | n/r | n/r | n/r | n/r | n/r |
| Cohort 2 | n/r | n/r | n/r | n/r | n/r |
| Cohort 3 | n/r | n/r | n/r | n/r | n/r |
| Cohort 4 | n/r | n/r | n/r | n/r | n/r |
| Cohort 5 | n/r | n/r | n/r | n/r | n/r |
| Cohort 6 | n/r | n/r | n/r | n/r | n/r |
| Cohort 7 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.